Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daprodustat versus epoetin alfa in hemodialysis patients with anemia of chronic kidney disease
2017-004372-56Phase 3Completed
- Sponsor
- GSK
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of daprodustat in anemia of renal disease and chronic kidney disease (CKD) (2 arms), sponsored by GSK. Primary endpoint: Mean change in hemoglobin between baseline and the evaluation period. Started Apr 2018; status: completed.
02
Drugs
daprodustat
03
Conditions
anemia of renal diseasechronic kidney disease (CKD)
Beyond the preview
Go deeper on 2017-004372-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004372-56.